Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. is classed by the SEC under Crude Petroleum & Natural Gas (industry code 1311), based in Dallas, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $5 million and a loss of $2 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a commodity producer: prior from its industry code (SEC 1311, Crude Petroleum & Natural Gas); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 1.5 out of ten, present 3.8 out of ten, future 5.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 1.9 out of ten. 7 warning events since 2017; the latest 2026-09-04. 19th percentile among 83 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 1.3 out of ten. +2.4% a year over 9 filed years; profitable in 0 of 9. 13th percentile among 74 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 0.9 out of ten. CrossAssetData estimate 0.9/10, confidence 35 of 100 (one part). 9th percentile among 78 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
- Financial health (present): 5.1 out of ten. ROE -56%: lost 56¢ per shareholder dollar. Leverage 37%: owes 37¢ per asset dollar. 51st percentile among 76 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 1.4 out of ten. bottom 15% of 76 in its family; net margin -48.1%. 15th percentile among 76 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 4.6 out of ten. bottom 46% of 51 in its family for leadership. 46th percentile among 51 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 2.9 out of ten. bottom 28% of 74 in its family for room to expand. 28th percentile among 74 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 3.5 out of ten. bottom 35% of 72 in its family for growth drivers. 35th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 8.3 out of ten. top 17% of 69 in its family for expectations against reality. 83rd percentile among 69 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-13 (on EDGAR). Newest filing: Form SCHEDULE 13G, 2026-09-30. Filings on record since 2009. Read from EDGAR 2026-10-12.
Who runs it
Comcowich, Kevin (director); Murray, Lilian Shackelford (director); Waller, Gregory D (director); Yoder, Amy (director). 4 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.